Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. CBER Consumer Affairs Branch or send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.

National Center for Immunization & Respiratory Diseases





U.S. Influenza Activity and Preliminary 2023-24 Influenza Vaccine Effectiveness Estimates

Lisa Grohskopf, MD, MPH
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention


Vaccines and Related Biological Products Advisory Committee March 5, 2024

Virologic Surveillance






Influenza-Like Illness (ILI) Activity—ILINet




Influenza-Associated Hospitalizations—FluSurv-NET



Pneumonia, and Influenza (P&I) Mortality—


National
Center for
Health
Statistics
Mortality
Surveillance
System

<u>CDC FluView</u> week ending February 24, 2023



Pediatric Mortality

<u>CDC FluView</u> week ending February 24, 2023



Summary as of the Week Ending February 24, 2024

- U.S. influenza activity has lessened slightly in recent weeks but is ongoing.
 - Percent of tests positive peaked at ~18% in late December; currently ~14%.
- Influenza A(H1N1)pdm09 viruses have predominated, with co-circulation of influenza A(H3N2) and B viruses.
- The cumulative influenza-associated hospitalization rate is 61.5/100,000.
- 93 influenza-associated pediatric deaths reported thus far this season.

National Center for Immunization & Respiratory Diseases



Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness

Originally presented by Aaron M. Frutos, PhD, MPH

On behalf of CDC Influenza Vaccine Effectiveness Collaborators

Advisory Committee on Immunization Practices

February 28, 2024


CDC Influenza Vaccine Effectiveness Networks

Four networks to evaluate vaccine effectiveness (VE) against laboratory-confirmed influenza for children, adolescents, and adults in the outpatient and inpatient settings

CDC Influenza Vaccine Effectiveness Networks

- Investigating Respiratory Viruses in the Acutely III (IVY)
 - Adults ≥18 years
 - Hospitalization
- New Vaccine Surveillance Network (NVSN)
 - Children/adolescents 6 months through 17 years
 - Outpatient visits, emergency department/urgent care, hospitalization
- U.S. Flu Vaccine Effectiveness Network (US Flu VE)
 - Children/adolescents 6 months through 17 years; adults ≥18 years
 - Outpatient visits, emergency department/urgent care
- Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network (VISION)
 - Children/adolescents 6 months through 17 years; adults ≥18 years
 - Emergency department/urgent care, hospitalization

CDC influenza VE networks include patients from 22 states



2023-2024 Influenza VE Methods

Enrollees: Have acute respiratory illness

Dates of enrollment: Fall 2023- Early 2024

Design: Test-negative design

- Comparing vaccination odds among case patients with influenza confirmed by molecular assay versus control patients testing negative for influenza and SARS-CoV-2
- Vaccination status: receipt of any 2023–24 seasonal flu vaccine according to medical records, immunization registries, claims data, and/or self-report

2023-2024 Influenza VE Methods

Analysis: $VE = (1 - adjusted OR) \times 100\%$

- Adjusted for geographic region, age, calendar time of illness
 - IVY, US Flu VE, and VISION also adjusted for sex and race and ethnicity
 - US Flu VE also adjusted for days between illness onset and enrollment and selfreported general health status.
- VE estimates were calculated for influenza A subtypes A(H1N1)pdm09 and A(H3N2) when possible
 - Subtype not available for VISION
- VE was not estimated for some age groups and settings when sample size was small or when models did not converge

Pediatric VE

(aged 6 months-17 years)

Pediatric VE against any influenza

	Influenza-positive	Influenza-negative	VE (95% CI)
NVSN (Outpatient)	123/622 (20)	793/2,577 (31)	59 (48, 67)
US Flu VE (Outpatient)	29/283 (10)	182/736 (25)	67 (48, 80)
VISION (Outpatient)	961/6,068 (16)	4,579/15,274 (30)	60 (57, 64)
NVSN (Inpatient)	29/128 (23)	543/1,321 (41)	61 (40, 75)
VISION (Inpatient)	21/113 (19)	299/921 (32)	52 (16, 72)

Pediatric VE against Influenza A

	Influenza-positive	Influenza-negative	VE (95% CI)
NVSN (Outpatient)	84/411 (20)	793/2,577 (31)	55 (41, 66)
US Flu VE (Outpatient)	27/212 (13)	182/736 (25)	46 (15, 67)
VISION (Outpatient)	920/5,524 (17)	4,579/15,274 (30)	59 (55, 62)
NVSN (Inpatient)	25/102 (25)	543/1,321 (41)	56 (30, 73)
VISION (Inpatient)	21/105 (20)	299/921 (32)	46 (7, 69)

Pediatric VE against Influenza A(H1N1)pdm09

	Influenza-positive	Influenza-negative	VE (95% CI)
NVSN (Outpatient)	61/298 (20)	793/2,577 (31)	54 (37, 66)
US Flu VE (Outpatient)	11/120 (9)	182/736 (25)	61 (26, 81)
NVSN (Inpatient)	18/79 (23)	543/1,321 (41)	60 (32, 77)

Pediatric VE against Influenza A(H3N2)

	Influenza-positive	Influenza-negative	VE (95% CI)
NVSN (Outpatient)	19/87 (22)	793/2,577 (31)	55 (20, 74)
US Flu VE (Outpatient)	2/17 (12)	182/736 (25)	Not estimated
NVSN (Inpatient)	4/10 (40)	543/1,321 (41)	Not estimated

Pediatric VE against Influenza B

	Influenza-positive	Influenza-negative	VE (95% CI)
NVSN (Outpatient)	39/216 (18)	793/2,577 (31)	64 (47, 75)
US Flu VE (Outpatient)	3/76 (4)	182/736 (25)	89 (70, 97)
VISION (Outpatient)	45/571 (8)	4,579/15,274 (30)	79 (71, 85)
NVSN (Inpatient)	4/27 (15)	543/1,321 (41)	Not estimated
VISION (Inpatient)	0/10 (0)	299/921 (32)	Not estimated

Adult VE

(aged ≥18 years)

Adult VE against any influenza

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	177/568 (31)	803/1,807 (44)	33 (16, 47)
VISION (Outpatient)	4,501/18,385 (24)	21,356/52,657 (41)	49 (47, 51)
IVY (Inpatient)	200/632 (32)	1,517/3,872 (39)	44 (32, 54)
VISION (Inpatient)	728/1,839 (40)	7,425/14,168 (52)	41 (34, 47)

Adult VE against Influenza A

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	168/495 (34)	803/1,807 (44)	27 (9, 43)
VISION (Outpatient)	4,343/15,896 (27)	21,356/52,657 (41)	46 (44, 48)
IVY (Inpatient)	80/264 (30)	1,517/3,872 (39)	42 (23, 57)
VISION (Inpatient)	713/1,742 (41)	7,425/14,168 (52)	40 (33, 47)

Adult VE against Influenza A(H1N1)pdm09

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	111/308 (36)	803/1,807 (44)	25 (1, 43)
IVY (Inpatient)	58/209 (28)	1,517/3,872 (39)	50 (30, 64)

Adult VE against Influenza A(H3N2)

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	14/67 (21)	803/1,807 (44)	54 (11, 77)
IVY (Inpatient)	18/45 (40)	1,517/3,872 (39)	Not estimated

Adult VE against Influenza B

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	9/76 (12)	803/1,807 (44)	78 (57, 90)
VISION (Outpatient)	164/2,530 (6)	21,356/52,657 (41)	78 (74, 81)
IVY (Inpatient)	5/21 (24)	1,517/3,872 (39)	Not estimated
VISION (Inpatient)	18/103 (17)	7,425/14,168 (52)	60 (30, 77)

Adult (aged 18–64) VE

Adult (aged 18–64) VE against any influenza

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	136/489 (28)	503/1,368 (37)	25 (3, 42)
VISION (Outpatient)	2,557/14,698 (17)	9,194/33,086 (28)	52 (50, 55)
IVY (Inpatient)	87/383 (23)	579/1,927 (30)	49 (33, 61)
VISION (Inpatient)	197/773 (25)	1,367/4,050 (34)	40 (28, 50)

Adult (aged 18–64) VE against Influenza A

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	128/417 (31)	503/1,368 (37)	13 (-13, 34)
VISION (Outpatient)	2,425/12,294 (20)	9,194/33,086 (28)	49 (46, 51)
IVY (Inpatient)	37/156 (24)	579/1,927 (30)	42 (13, 61)
VISION (Inpatient)	187/694 (27)	1,367/4,050 (34)	38 (24, 48)

Adult (aged 18–64) VE against Influenza B

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	8/75 (11)	503/1,368 (37)	75 (50, 89)
VISION (Outpatient)	135/2,433 (6)	9,194/33,086 (28)	79 (75, 82)
IVY (Inpatient)	2/16 (12)	579/1,927 (30)	Not estimated
VISION (Inpatient)	13/83 (16)	1,367/4,050 (34)	50 (5, 74)

Adult (aged ≥65) VE

Adult (aged ≥65) VE against any influenza

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	41/79 (52)	300/439 (68)	51 (14, 72)
VISION (Outpatient)	1,944/3,687 (53)	12,162/19,571 (62)	41 (36, 45)
IVY (Inpatient)	113/249 (45)	938/1,945 (48)	42 (23, 56)
VISION (Inpatient)	531/1,066 (50)	6,058/10,118 (60)	42 (34, 50)

Adult (aged ≥65) VE against Influenza A

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	40/78 (51)	300/439 (68)	52 (16, 73)
VISION (Outpatient)	1,918/3,602 (53)	12,162/19,571 (62)	40 (36, 45)
IVY (Inpatient)	43/108 (40)	938/1,945 (48)	47 (19, 65)
VISION (Inpatient)	526/1,048 (50)	6,058/10,118 (60)	42 (34, 49)

Adult (aged ≥65) VE against Influenza B

	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	1/1 (100)	300/439 (68)	Not estimated
VISION (Outpatient)	29/97 (30)	12,162/19,571 (62)	69 (51, 80)
IVY (Inpatient)	3/5 (60)	938/1,945 (48)	Not estimated
VISION (Inpatient)	5/20 (25)	6,058/10,118 (60)	Not estimated

Summary

Summary of four CDC influenza VE networks

Vaccination with a 2023-24 influenza vaccine **reduced the risk for** medically attended influenza **outpatient visits** and **hospitalizations** among **children**, **adolescents**, **and adults across 22 US States**

Vaccination was effective against **both influenza A (mostly subtype A(H1N1)pdm09) and B (lineage Victoria) viruses** that have circulated this season

Results were consistent across networks

Thank you

Lisa A. Grohskopf, MD, MPH

Influenza Division

National Center for Immunization and Respiratory Diseases

LGrohskopf@cdc.gov

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

Thanks to:

- CDC Influenza Division
 Epidemiology and Prevention
 Branch Surveillance Team and
 Influenza Prevention and Control
 Team
- The many surveillance network contributors and collaborators from CDC, IVY, NVSN, US Flu VE, and VISION

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

